Cover Image
市場調查報告書

CIMAB S.A.的產品平台分析

CIMAB S.A. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 317359
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
CIMAB S.A.的產品平台分析 CIMAB S.A. - Product Pipeline Review - 2014
出版日期: 2014年10月25日 內容資訊: 英文 35 Pages
簡介

CIMAB S.A.是總公司位於古巴的生物製藥企業,正在開發並商品化癌症和免疫系統相關疾病的治療及診斷用單株抗體以及其他基因重組蛋白質。其產品有胰臟、胃、食道、頭頸椎、肺、子宮、腦等癌症的治療藥。

本報告提供CIMAB S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

CIMAB S.A.的基本資料

  • CIMAB S.A.概要
  • 主要資訊
  • 企業資料

CIMAB S.A.:R&D概要

  • 主要的治療範圍

CIMAB S.A.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

CIMAB S.A.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

CIMAB S.A.:藥物簡介

  • CIMAvax-EGF Peptide Vaccine
  • epoetin alfa
  • Monoclonal Antibody to Inhibit CD20 for Non-Hodgkin Lymphoma and Rheumatoid Arthritis
  • Vaccine for Epithelial Cancer
  • 14-F7 MAb
  • Monoclonal Antibody to Inhibit HER2 for Breast Cancer
  • Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis
  • Monoclonal Antibody to Inhibit VEGF for Cancer
  • Pegylated Recombinant Human Erythropoietin Alpha
  • Recombinant Protein to Agonize IL-2 for Cancer
  • Vaccine for Atherosclerosis
  • Vaccine for Cancer

CIMAB S.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

CIMAB S.A.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06212CDB

Summary

Global Markets Direct's, 'CIMAB S.A. - Product Pipeline Review - 2014', provides an overview of the CIMAB S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CIMAB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CIMAB S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CIMAB S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CIMAB S.A.'s pipeline products

Reasons to buy

  • Evaluate CIMAB S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CIMAB S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CIMAB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CIMAB S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CIMAB S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CIMAB S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CIMAB S.A. Snapshot
    • CIMAB S.A. Overview
    • Key Information
    • Key Facts
  • CIMAB S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • CIMAB S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • CIMAB S.A. - Pipeline Products Glance
    • CIMAB S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • CIMAB S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CIMAB S.A. - Drug Profiles
    • CIMAvax-EGF Peptide Vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD20 for Non-Hodgkin Lymphoma and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Epithelial Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 14-F7 MAb
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit HER2 for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit VEGF for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Recombinant Human Erythropoietin Alpha
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize IL-2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Atherosclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CIMAB S.A. - Pipeline Analysis
    • CIMAB S.A. - Pipeline Products by Target
    • CIMAB S.A. - Pipeline Products by Route of Administration
    • CIMAB S.A. - Pipeline Products by Molecule Type
    • CIMAB S.A. - Pipeline Products by Mechanism of Action
  • CIMAB S.A. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CIMAB S.A., Key Information
  • CIMAB S.A., Key Facts
  • CIMAB S.A. - Pipeline by Indication, 2014
  • CIMAB S.A. - Pipeline by Stage of Development, 2014
  • CIMAB S.A. - Monotherapy Products in Pipeline, 2014
  • CIMAB S.A. - Partnered Products in Pipeline, 2014
  • CIMAB S.A. - Partnered Products/ Combination Treatment Modalities, 2014
  • CIMAB S.A. - Phase II, 2014
  • CIMAB S.A. - Phase I, 2014
  • CIMAB S.A. - Preclinical, 2014
  • CIMAB S.A. - Discovery, 2014
  • CIMAB S.A. - Pipeline by Target, 2014
  • CIMAB S.A. - Pipeline by Route of Administration, 2014
  • CIMAB S.A. - Pipeline by Molecule Type, 2014
  • CIMAB S.A. - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • CIMAB S.A. - Pipeline by Top 10 Indication, 2014
  • CIMAB S.A. - Pipeline by Stage of Development, 2014
  • CIMAB S.A. - Monotherapy Products in Pipeline, 2014
  • CIMAB S.A. - Partnered Products in Pipeline, 2014
  • CIMAB S.A. - Pipeline by Top 10 Target, 2014
  • CIMAB S.A. - Pipeline by Top 10 Molecule Type, 2014
  • CIMAB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top